Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria by van Roosmalen, ML et al.
  
 University of Groningen
Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-
grade bacteria
van Roosmalen, ML; Kanninga, R; El Khattabi, M; Neef, J; Audouy, S; Bosma, T; Kuipers, A;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2006
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van Roosmalen, ML., Kanninga, R., El Khattabi, M., Neef, J., Audouy, S., Bosma, T., ... Leenhouts, K.
(2006). Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade
bacteria. Methods., 38(2), 144-149. https://doi.org/10.1016/j.ymeth.2005.09.015
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Methods 38 (2006) 144–149
www.elsevier.com/locate/ymethMucosal vaccine delivery of antigens tightly bound to an adjuvant 
particle made from food-grade bacteria
Maarten L. van Roosmalen a, Rolf Kanninga a, Mohamed El Khattabi a, Jolanda Neef a, 
Sandrine Audouy a, Tjibbe Bosma a, Anneke Kuipers a, Eduard Post a, Anton Steen b, 
Jan Kok b, Girbe Buist b, Oscar P. Kuipers b, George Robillard a, Kees Leenhouts a,¤
a BiOMaDe Technology Foundation, Nijenborgh 4, 9747 AG Groningen, The Netherlands
b Groningen Biomolecular Science and Biotechnology Institute, Department of Genetics, University of Groningen, Kerklaan 30, 
9751 NN Haren, The Netherlands
Accepted 22 September 2005
Abstract
Mucosal immunization with subunit vaccines requires new types of antigen delivery vehicles and adjuvants for optimal immune
responses. We have developed a non-living and non-genetically modiWed gram-positive bacterial delivery particle (GEM) that has built-in
adjuvant activity and a high loading capacity for externally added heterologous antigens that are fused to a high aYnity binding domain.
This binding domain, the protein anchor (PA), is derived from the Lactococcus lactis AcmA cell-wall hydrolase, and contains three
repeats of a LysM-type cell-wall binding motif. Antigens are produced as antigen–PA fusions by recombinant expression systems that
secrete the hybrid proteins into the culture growth medium. GEM particles are then used as aYnity beads to isolate the antigen–PA
fusions from the complex growth media in a one step procedure after removal of the recombinant producer cells. This procedure is also
highly suitable for making multivalent vaccines. The resulting vaccines are stable at room temperature, lack recombinant DNA,
and mimic pathogens by their bacterial size, surface display of antigens and adjuvant activity of the bacterial components in the GEM
particles. The GEM-based vaccines do not require additional adjuvant for eliciting high levels of speciWc antibodies in mucosal and
systemic compartments.
 2005 Elsevier Inc. All rights reserved.
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1.1. Mucosal immunization
Conventional vaccine delivery technologies are based on
injection into the body of a mixture of protective compo-
nents and an immunostimulatory agent. While this paren-
teral route of immunization has proven to be eVective, it
often lacks stimulation of local immunity at the site, where
most pathogens enter the body: the mucosal surface. The
most eVective way to induce mucosal immunity (secretory
* Corresponding author.
E-mail address: leenhouts@biomade.nl (K. Leenhouts).1046-2023/$ - see front matter  2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.ymeth.2005.09.015IgA) is to administer a vaccine directly to the mucosal sur-
face. M-cells in the upper nasopharyngeal tissue are capable
of antigen uptake and subsequent transport to the profes-
sional antigen presenting cells (APCs) which can elicit local
and distal mucosal as well as systemic immune responses
[1]. Peyer’s patches in the intestinal tract (GALT) and naso-
pharyngeal-associated lymphoreticular tissue (NALT) in
the nasal cavity are part of the common mucosal immune
system, capable of eVectively inducing antigen-speciWc T-
helper (Th), cytotoxic T lymphocytes (CTLs), and IgA B-
cell responses [2,3]. In addition to stimulating local immu-
nity, mucosal vaccination has the beneWts of needle-free
administration, reduced side-eVects, easy boosting, and can
be used for mass vaccination. Furthermore, it is increasingly
M.L. van Roosmalen et al. / Methods 38 (2006) 144–149 145more diYcult to implement new injectable vaccines into
existing pediatric vaccination programs for which the num-
ber of injections is limited; a problem that can be circum-
vented by mucosal vaccination.
In spite of the ease of mucosal administration, safe, eVec-
tive, and aVordable carrier and adjuvant systems that are
essential for these types of vaccines are still lacking. Bacte-
rial carrier systems are easy to produce and have built-in
adjuvant activity. Attenuated strains of bacterial pathogens
such as Salmonella typhi, Mycobacterium bovis, and Borde-
tella pertussis are being developed as recombinant vectors
for mucosal immunization, but suVer from the disadvan-
tage that they tend to disseminate in the body [1], have the
risk of transferring recombinant DNA to other organisms
and can be hazardous in immunocompromised people.
Bacterial ghosts made from gram-negative bacteria like
Escherichia coli reduce some of these risks. They are non-
living and can be used as antigen delivery particles [4,5].
These ghosts are empty cell envelopes made by protein-E-
mediated lysis which have retained almost all morphologi-
cal and structural features of the natural cell. They contain
some well-known immune stimulating compounds such as
lipopolysaccharide (LPS), Lipid A, and peptidoglycan and
are capable of stimulation of both cellular and humoral
arms of the immune system [6]. However, the presence of
LPS in the gram-negative cell wall has been suggested as a
potential problem for human applications, although it did
not induce fever in test animals [7]. In any case, these bacte-
rial ghosts are derived from genetically modiWed organisms
(GMO) and the presence of residual amounts of recombi-
nant DNA in non-lysed cells may constitute an obstacle for
the application of this carrier system in mucosal vaccines.
The antigen display and delivery system described here,
named the MimoPath system, is based on non-genetically
modiWed gram-positive bacteria. It consists of non-living
bacterial shaped delivery particles with adjuvant properties,
which are loaded with antigens containing a cell-wall bind-
ing domain, called the protein anchor (PA, Fig. 1) [8]. The
particles, referred to as gram-positive enhancer matrix
(GEM), are made from acid-pretreated Lactococcus lactisbacteria. These GEM particles retain their original size and
structure, of about 1m, and are thus ideally sized for
uptake by the M-cells on the mucosal surface. Antigens can
be produced as fusion proteins with the PA. These antigen–
PA fusions bind non-covalently with high aYnity to the
peptidoglycan from GEM particles when mixed in solution
(in trans binding). The result is a vaccine that mimics
pathogens, producing a bacterial particle containing pepti-
doglycan with antigenic proteins exposed on its surface. An
important advantage of the MimoPath system compared
with recombinant bacterial delivery systems is the lack of
recombinant DNA. Thus, it minimizes the risks associated
with the spread of recombinant DNA into the environ-
ment, which is especially relevant in the case of wide-spread
mucosal administration of vaccines.
1.2. The protein anchor
The protein anchor (PA) is made up of three LysM
motifs of about 45 amino acids, separated by spacer
regions. The LysM motif is a common module found in
many cell-wall degrading enzymes and proteins involved in
bacterial pathogenesis and is often present in multiple
repeats [9–11]. It has been proposed that the LysM-type
cell-wall binding domain binds non-covalently to peptido-
glycan of various gram-positive bacteria [12]. The LysM
motif has also been found in a number of eukaryotic pro-
teins [10], and it was recently demonstrated that LysM
domains are involved in recognition of symbiotic bacteria
by the roots of plants [13–15]. In L. lactis, following secre-
tion of the AcmA cell-wall hydrolase, the PA directs the
protein to the cell wall. Hybrid PA fusion proteins, like
MSA2, -lactamase, -amylase, viral capsid proteins and
FedF-PA fusions show similar properties [8,16–18].
1.3. The GEM particle
In all experiments with PA fusion proteins, it was
observed that only a small amount of the secreted PA
fusions bind to the L. lactis producer cells. Most of theFig. 1. Production of a vaccine: binding of PA fusions to GEM particles. In a two-step procedure, antigens containing a protein anchor domain (PA) and
a gram-positive enhancer matrix (GEM) particle of bacterial origin are used to make a vaccine. First, the antigen–PA fusions are produced in the medium
and separated from the producer cells. Next, GEM particles and cell-free medium are mixed. The PA directs the antigens to the surface of the GEM parti-
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tant. In a number of cases, it was demonstrated that the PA
fusions in the growth medium can be used to bind to non-
producer L. lactis cells, albeit again in small amounts
[12,18]. Steen et al. [12] discovered that boiling of L. lactis
whole cells in trichloroacetic acid (TCA) followed by wash-
ing and neutralization prior to binding, dramatically
increased the amount of MSA2-PA that can be bound to
the cells. Other acid-pretreated gram-positive bacteria like
Lactobacillus ssp. also showed increased binding capacity,
suggesting that this method is applicable for production of
GEM particles from a wider range of bacteria [12]. Since
L. lactis is a GRAS organism (generally recognized as safe),
lacks endotoxic LPS and lactococcal GEM particles do not
contain recombinant DNA, safety issues are anticipated to
be limited.
Binding of the PA to GEM particles is non-covalent, but
very strong and approximately one million PA molecules
can be bound on to one particle [31]. So far, only treatment
with SDS sample buVer or 8 M LiCl was able to partially
release the PA (patent WO02101026 [19]).
1.4. The MimoPath display and delivery system
EYcient and selective cell-surface binding to GEM
particles occurs after addition of cell-free culture medium
from recombinant producer strains that secrete chimeric
PA-fusion proteins, without the need for additional puri-
Wcation steps. Bosma et al. [31] have shown the versatility
and Xexibility of this system by functional display of two
enzymes, -amylase and -lactamase, in diVerent ratios
onto the surface of GEM particles. PA-mediated surface
display diVers in a number of aspects from bacterial sur-
face display and delivery systems known to date [20].
First, PA-containing fusions are added from the outside
to gram-positive cells (in trans binding). Second, the
strain for production of hybrid PA-containing proteins
and the host strain for surface display are diVerent, allow-
ing the use of a non-GMO delivery vehicle. In contrast,
current bacterial display systems rely on recombinant
host strains, in which the anchoring domain is covalently
attached to the cell surface during translocation [21].
Third, multiple PA fusions can be bound on to one parti-
cle in adjustable ratios, allowing the production and
delivery of multivalent vaccines. Alternatively, monova-
lent vaccines can be mixed together in diVerent ratios
facilitating Xexible vaccine compositions. Finally, PA
fusions can be bound to living as well as to non-living
gram-positive bacteria.
Here, we describe the production and use of GEM-based
vaccines. The construction and expression of antigen–PA
fusions and the construction of GEM particles from L. lac-
tis are described in detail. Furthermore, we show that
GEM-bound PA is highly stable for long periods of time.
Also, the use of a GEM-based vaccine for induction of
serum IgG and local secretory IgA is demonstrated in an
animal model.2. Detailed methods
2.1. General molecular biology
Strains and plasmids used in this study are listed in
Table 1. L. lactis strains were grown in standing cultures at
30 °C in M17 broth (Oxoid, The Netherlands) containing
0.5 % glucose (w/v) (GM17) and, when necessary, supple-
mented with 5g/ml chloramphenicol (GM17Cm5). Phos-
phate-buVered saline (PBS) contained 58 mM Na2HPO4,
17 mM NaH2PO4, and 68 mM NaCl at pH 7.2. Enzymes
and buVers were purchased from New England Biolabs
(USA) or Roche (The Netherlands). Electro-transforma-
tion of L. lactis was carried out as described previously [22]
using a Bio-Rad Gene Pulser (Bio-Rad, The Netherlands).
2.2. Antigen–protein anchor fusions
For easy production of antigen–PA fusions, the pPA90
vector was constructed. This vector contains the following
features (Fig. 2): the lactococcal pNZ212 origin of replica-
tion; a chloramphenicol acetyltransferase gene for selection;
the PnisA promoter to direct inducible expression of PA
fusions [23]; the lactococcal USP45 secretion signal to drive
secretion [24]; the gene fragment encoding the PA (the C-ter-
minal 218 amino acid cell-wall binding domain of AcmA of
L. lactis [25] including its stop codon); and a transcriptional
Table 1
Bacterial strains and plasmids
























Derivative of NZ9000 lacking 
acmAand htrA
[31]
pPA3 Cmr, pNZ8048 derivative 
containing c-myc, the acmA PA 
(nt 835–1492) under control PnisA 
and usp45ss (PA3)
[12]
pPA90 Cmr, pPA3 derivative lacking the 
c-myc epitope (PA90)
This study
Fig. 2. The pPA90 vector. Schematic representation of a part of the gen-
eral display vector pPA90. Abbreviations: PnisA, inducible nisA promoter;
usp45ss, usp45 signal sequence; NcoI, restriction site for integration of anti-
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fragment. Genes can be inserted in the unique NcoI site,
resulting in a transcriptional fusion with the Met residue
located at position +5 of the mature secreted protein.
2.3. Overexpression of PA-fusion proteins in L. lactis
Although it is possible to produce PA-fusion proteins
secreted by Bacillus subtilis or by intracellular expression in
L. lactis (data not shown), secretion by L. lactis into the
medium is the standard production method. PA-fusion pro-
teins can be produced by L. lactis PA1001, a MG1363
derived strain lacking acmA and htrA genes, and containing
the nisRK genes needed for nisin induced expression. The
housekeeping protease HtrA has been shown to degrade
the AcmA cell-wall binding domain [25–27] and strains
lacking htrA are more eYcient in production of PA con-
taining proteins. Lack of the acmA gene causes the bacteria
to grow in strings, since the hydrolase needed for cell sepa-
ration is absent [25].
In a typical production experiment, L. lactis PA1001
containing a pPA90-derived vector coding for an anti-
gen–PA fusion protein, was grown overnight in
GM17Cm5 at 30 °C in standing cultures. Subsequently,
the cells were diluted 100-fold in 1 l of fresh pre-warmed
(30 °C) GM17Cm5. At a cell density OD600 of 0.5, expres-
sion of the PA-fusion protein was induced by addition of
1 ml of cell-free nisin-containing supernatant produced
from an overnight culture of L. lactis NZ9700. The induc-
tion was repeated at OD600 of 1.0. After each addition of
nisin-containing supernatant the culture was thoroughly
mixed and then left standing to grow at 30 °C for a total
of 24 h before cells and supernatant were separated by
centrifugation for 10 min at 13,000g. The supernatant was
either used directly for binding after Wlter-sterilization
(0.45 m), or concentrated Wrst with a VivaFlow 200
(10 kDa molecular mass cut oV) and Wlter-sterilized again.
Concentration of the culture supernatant may be used,
when production levels are low and in general this
increases the amount of bound PA-fusion protein to
GEM particles.
2.4. Production of the GEM particles
Chemical pre-treatment of L. lactis MG1363 to gener-
ate GEM particles was performed as follows. Cells from a
fresh overnight culture were diluted 100-fold in 500 ml of
fresh GM17 and the standing culture was left to grow for
16 h at 30 °C. Cells were collected by centrifugation
(10 min, 13,000g) and washed once by the addition of
250 ml sterile distilled water, vortexed, and centrifuged.
Subsequently, 100 ml acid solution was added to the pel-
let and the cell suspension was placed in boiling water for
30 min in a tube under atmospheric pressure. When larger
volumes were used, 1 l bottles containing a maximum of
300 ml cell suspension were steamed in a sterilizing
pressure cooker with an unscrewed lid for 30 min atatmospheric pressure. The acid solution contained either
0.1 M HCl, 0.6 M TCA or 0.05 M H2SO4 in water which
corresponds with an acidity of pH 1. The pH is known to
be the critical factor in successful GEM production, not
the type of acid. Next, the cells were washed three times in
250 ml sterile PBS with vigorous vortexing. After the last
washing step, cells were taken up in 50 ml PBS. The num-
ber of GEM particles per milliliter was determined micro-
scopically with a Bürker–Turk counting chamber. One
unit (U) is deWned as 2.5 £ 109 GEM particles and stan-
dard stock solutions containing 10 U/ml were stored at
¡80 °C. The dry weight of GEM particles is approxi-
mately 250 g/U. The GEM particles generated in this
way are capable of binding 10–15 times more PA proteins
than untreated L. lactis cells. Furthermore, the morphol-
ogy of these particles remains almost identical to their
untreated precursor cells. The DNA content (non-recom-
binant) is reduced by a factor of one million, as deter-
mined by real-time quantitative PCR, and the treatment
resulted in complete killing of all cells (T. Bosma, submit-
ted for publication).
2.5. Binding of PA-containing proteins to GEM particles
Protein anchor fusion proteins quickly bind to GEM
particles when added together in solution. The standard
procedure is to add one unit GEM particles to 2 ml PA-
containing culture supernatant and slowly mix it on a
rotating blood suspension mixer for up to 30 min. When
concentrated, puriWed PA is used, binding occurs in sec-
onds during mixing. After binding, GEM particles are
washed in PBS and resuspended in their original volume.
We were unable to demonstrate, by quantitative rtPCR,
the presence of recombinant DNA in GEM-based vac-
cines that could have been included by non-speciWc bind-
ing of recombinant plasmid DNA, released by lysis of
producer cells.
2.6. Stability of bound protein
Stability of the GEM-bound protein anchor over time
was determined under the inXuence of diVerent storage
conditions like temperature, buVer components, and dry-
ing. L. lactis PA1001 (pPA3) was induced with nisin as
described before to produce the PA3 protein. PA3 is simi-
lar to PA90 but contains an N-terminal c-myc epitope for
easy immunological detection. The GEM particles were
made from L. lactis NZ9000acma using TCA as acid.
For each group, 2 ml of PA3-containing supernatant was
bound to one unit GEM particles. The GEM particles
were washed with water or PBS and stored at three diVer-
ent temperatures (¡80, 4 °C, and room temperature [10–
30 °C]) in solution or as freeze-dried powder. After 1, 2, 3,
6, and 12 months the particles were subjected to SDS–
PAGE and Western blotting to determine the amount
and stability of bound PA3 (Fig. 3). After one year, PA3
was still bound to GEM particles and remained intact.
148 M.L. van Roosmalen et al. / Methods 38 (2006) 144–149The best freeze-dried formulation was obtained when
the GEM particles were dried in water. Freeze drying
in PBS resulted in a hard pellet that was diYcult to
resuspend. When the particles were examined by micros-
copy, no visible diVerence in particle size was observed
(data not shown). These results show that GEM-bound
PA can be stored as a freeze-dried powder at room tem-
perature for at least one year without any sign of degra-
dation of its components. This indicates that a cold-chain
route for delivery of GEM-based vaccines can be
avoided.
Fig. 3. Stability of GEM-PA after one year of storage. (A) The PA3 pro-
tein of approximately 26 kDa is visible as a band of slightly shorter run-
ning distance on this Coomassie brilliant blue-stained protein gel with
samples from GEM-PA3. Samples were kept for one year at diVerent stor-
age conditions, indicated above the Wgure. The intensity of all PA3 signals
is approximately equal, except for the PA3 in the lane with GEM-PA3
that was freeze dried in PBS and stored at room temperature, which could
not be fully resuspended. The background smear that is present in all lanes
originates from residual degraded proteins in the GEM particles. (B) Anti-
bodies against the c-myc epitope present in this PA3 were used to detect
the PA in a Western blot containing the same samples as in (A).3. Applications
3.1. Induction of local and systemic antibodies by mucosal 
immunization using the MimoPath system
The use of GEM-based vaccines as eYcient delivery sys-
tem for mucosal vaccination was shown by induction of
serum IgG and secretory IgA in nasally immunized mice by
Audouy et al. (S. Audouy, submitted for publication). Two
pneumococcal antigens, SlrA and PpmA, were produced as
PA fusion proteins and separately bound to GEM particles,
resulting in two monovalent vaccines that contained
either 73g/U SlrA-PA or 17g/U PpmA-PA antigen. Two
groups of mice, each receiving one monovalent vaccine,
were immunized nasally with 3 doses given at 10-day
intervals. Each dose contained one unit (2.5 £ 109) GEM
particles. The mice were killed 20 days after the last immu-
nization. At killing blood samples, nose and lung lavages
(with 0.5 and 1 ml PBS containing protease inhibitor, respec-
tively) were collected and the amount of antigen-speciWc
IgG and IgA was determined using ELISA techniques. For
this purpose, ELISA microtiter plates were coated with
puriWed His-tagged variants of the two antigens (0.2g/
well). Plates were washed with PBS (pH 7.4) with 0.02% (v/
v) Tween 20, then incubated 1 h with 1% (w/v) BSA in PBS/
Tween. Sera were diluted, added to the plates in threefold
dilutions and incubated for 2 h at room temperature. After
washing, the alkaline phosphatase conjugated secondary
antibody directed to mouse IgA or IgG was incubated for
1.5 h at a dilution of 1:5000. Colorimetric reaction was
obtained by addition of p-nitrophenyl phosphate substrate.
As shown in Table 2, both GEM-based vaccines were capa-
ble of stimulating high levels of antigen-speciWc secretory
IgA as well as circulating serum IgG antibodies against
both displayed antigens.
4. Discussion
We have described a method to make a GEM-bound
antigen delivery vehicle, called the MimoPath system,
using a number of steps. First, GEM particles are produced
by hot acid pre-treatment of gram-positive L. lactis bacte-
ria. The bacterial-sized GEM particles are devoid of most
proteins, DNA and cellular components and show
enhanced binding capacity for proteins containing the
Table 2
Secretory IgA and serum IgG levels in vaccinated mice (means § SEM)
Two groups of mice, each receiving one monovalent vaccine, were immu-
nized nasally with 3 doses given at 10-day intervals. Antigen-speciWc IgG
and IgA levels were measured 20 days after the last immunization in
blood samples, nose and lung lavages with ELISA (S. Audouy, submitted
for publication). No speciWc antibody was detected in mice that received
PBS only.
Anti-SlrA (n D 3) Anti-PpmA (n D 4)
Nose IgA (ng/ml) 256 (§108) 110 (§ 38)
Lung IgA (ng/ml) 45 (§20) 28 (§ 21)
Serum IgG (g/ml) 178 (§32) 207 (§ 102)
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fusions are secreted into the growth medium of an L. lactis
producer strain. The cell-free medium can be used directly,
or can be concentrated by ultraWltration before binding. No
inactivation procedures that denature relevant immuno-
genic determinants are employed. Finally, GEM particles
and PA-fusion protein containing medium are mixed and
as a result the PA fusions bind tightly to the peptidoglycan
present in the GEM particles. Immobilization of PA
fusions is fast and easy without the need for chemical treat-
ments or extensive puriWcation steps. Multivalent vaccines
can be made by attachment of diVerent antigen–PA fusions
to the same particle, or by a mixture of monovalent vac-
cines. In our laboratory, we have successfully made and
used a pentavalent vaccine against Streptococcus pneumo-
niae using both formulations (data not shown).
Vaccines based on the MimoPath delivery system circum-
vent some of the drawbacks associated with the use of genet-
ically modiWed bacterial delivery systems. These GEM-based
vaccines would also be very suitable for use in developing
countries: they enable needle-free administration, allow easy
immunization of large populations, and most likely they can
be transported and stored for a long period without the need
for a cold chain. Furthermore, these vaccines are easy to pro-
duce, can induce an immune response at distant mucosal sites
(data not shown), and are based on a GRAS organism that is
also present in dairy products for human consumption. Cur-
rently, we are using the MimoPath system to evaluate its
eYcacy in animal models of diseases from bacterial, viral,
and parasitic origin.
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